Rocket Pharmaceuticals (RCKT) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to 0.85.
- Rocket Pharmaceuticals' Equity Ratio rose 174.77% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year increase of 174.77%. This contributed to the annual value of 0.88 for FY2024, which is 92.99% up from last year.
- As of Q3 2025, Rocket Pharmaceuticals' Equity Ratio stood at 0.85, which was up 174.77% from 0.84 recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Equity Ratio registered a high of 0.92 during Q3 2021, and its lowest value of 0.83 during Q1 2021.
- Over the past 5 years, Rocket Pharmaceuticals' median Equity Ratio value was 0.88 (recorded in 2022), while the average stood at 0.88.
- In the last 5 years, Rocket Pharmaceuticals' Equity Ratio skyrocketed by 2706.17% in 2021 and then tumbled by 730.67% in 2024.
- Over the past 5 years, Rocket Pharmaceuticals' Equity Ratio (Quarter) stood at 0.91 in 2021, then decreased by 3.0% to 0.89 in 2022, then dropped by 1.99% to 0.87 in 2023, then rose by 0.93% to 0.88 in 2024, then decreased by 2.91% to 0.85 in 2025.
- Its last three reported values are 0.85 in Q3 2025, 0.84 for Q2 2025, and 0.87 during Q1 2025.